Indaptus Therapeutics Inc Stock Price, News & Analysis

Indaptus Therapeutics (Nasdaq: INDP), a clinical stage biotechnology company, has announced a 1-for-28 reverse stock split effective after market close on June 26, 2025. The stock will begin trading on a split-adjusted basis on June 27, 2025, under the same symbol "INDP" but with a new CUSIP number.

The reverse split, approved by stockholders on June 10, 2025, aims to regain Nasdaq listing compliance and attract institutional investors. The split will reduce outstanding shares from approximately 16 million to 572 thousand. Proportionate adjustments will be made to outstanding options and warrants, with cash payments issued for fractional shares based on the closing price on June 26, 2025.

Indaptus Therapeutics (NASDAQ: INDP) has secured $2.3 million through a private placement of convertible notes and warrants, led by a healthcare-focused institutional investor, as part of a larger offering targeting up to $5 million. The notes, maturing on July 28, 2026, carry a 6% annual interest rate and will convert to common stock at 80% of the average closing price over five trading days, capped at $0.40 per share. Investors will receive warrants to purchase 200% of conversion shares, exercisable for five years at the notes' conversion price. The proceeds will fund research and development, including a Phase 1b/2 clinical trial, working capital, and general corporate purposes. Paulson Investment Company is serving as the exclusive placement agent for this offering.

Indaptus Therapeutics (NASDAQ: INDP) has initiated dosing in a new Phase 1b/2 clinical trial arm evaluating Decoy20 in combination with BeOne's PD-1 checkpoint inhibitor tislelizumab. The study focuses on patients with advanced solid tumors who either previously received checkpoint inhibitor treatment or have tumors typically unresponsive to checkpoint inhibitors. The trial aims to assess safety, optimize dosing, and evaluate preliminary anti-tumor activity. Preclinical data has shown synergistic effects between Decoy20 and checkpoint inhibitors, suggesting potential enhanced immune responses. The company believes this combination therapy could benefit patients who don't respond to traditional checkpoint inhibitor treatments.

Indaptus Therapeutics (NASDAQ: INDP) reported Q1 2025 financial results and provided corporate updates. Key highlights include the initiation of a Phase 1b/2 combination study of Decoy20 with PD-1 checkpoint inhibitor Tislelizumab. The company has enrolled 32 patients in weekly dosing trials, showing Decoy20 is well-tolerated with encouraging stable disease cases. Financial results show R&D expenses increased to $2.8M (vs $1.6M in Q1 2024), while G&A expenses decreased to $1.8M (vs $2.4M). Loss per share improved to $0.32 (vs $0.45). Cash position stands at $3.9M as of March 31, 2025, down from $5.8M in December 2024. The company implemented a cost-reduction plan and expanded its patent portfolio in China, Japan, and Israel, but will need additional capital beyond Q2 2025.

Indaptus Therapeutics (INDP) announces that its Founder and Chief Scientific Officer, Dr. Michael Newman, will take a prominent role at the 6th Annual Cytokine-Based Drug Development Summit in Boston on May 15-16, 2025. Dr. Newman will serve as Chair of Day 2 and deliver a presentation on "Pulsed Cytokine Delivery for Anti-Tumor Immunotherapy & its Impact on Toxicity & Efficacy" on May 15. He will also lead a panel discussion on pre-clinical models and deliver opening and closing remarks.

The summit, hosted by HansonWade, brings together industry leaders to discuss cytokine drug development challenges and solutions. CEO Jeffrey Meckler highlighted that this invitation demonstrates recognition of the company's novel Decoy platform and Dr. Newman's leadership in cytokine research.

Indaptus Therapeutics (Nasdaq: INDP) announces that Chief Medical Officer Roger Waltzman, M.D., M.B.A. will moderate a panel at the upcoming CMO360 Summit in Boston on April 7-8, 2025. The panel, titled 'Ensuring Effective and Efficient Trials Through Clinical Operations,' is scheduled for April 7th from 4:05PM to 4:35PM ET.

The CMO Summit 360°, operated by The Conference Forum, represents the largest gathering of biotech Chief Medical Officers across various indications, modalities, company stages, and locations. CEO Jeffrey Meckler views this participation as validation of the company's approach to clinical trial management.

Indaptus Therapeutics (NASDAQ: INDP) has reported new data from the weekly dosing cohort of its Phase 1 trial of Decoy20, showing successful broad immune system activation. The trial has enrolled over 20 patients, with the 30 million cell dose demonstrating general tolerability and a favorable safety profile.

Key findings reveal that Decoy20 treatment triggers:

• Short-term increases in immune system biomarkers (cytokines and chemokines)
• Broad blood-based immune cell trafficking
• Transient weekly fluctuations in innate and adaptive immune cell levels

Some patients have shown stable disease in early clinical observations. The company has initiated a new Phase 1b/2 trial arm combining Decoy20 with BeiGene's PD-1 checkpoint inhibitor, tislelizumab, focusing on safety, dose optimization, and preliminary anti-tumor activity.

Indaptus Therapeutics (INDP) has initiated a new expansion arm in its Phase 1b/2 clinical trial, combining Decoy20 with BeiGene's PD-1 checkpoint inhibitor, tislelizumab. The study will evaluate safety, dosing, and preliminary anti-tumor activity in advanced solid tumors.

The expansion marks a significant development in testing Decoy20's synergistic potential with checkpoint inhibitors in patients for the first time. The combination aims to address the limitations of current checkpoint inhibitor treatments, where many patients either don't respond or don't experience lasting effects.

Decoy20 is designed to activate the immune system in a way that could potentially enhance and expand the effectiveness of checkpoint inhibitors, representing a possible breakthrough in solid tumor treatment approaches.

Indaptus Therapeutics (NASDAQ: INDP) has reported significant progress in its Phase 1 trial of Decoy20, with over 20 patients enrolled in the weekly dosing cohort. The company has observed promising early results, including stable disease in some patients and favorable safety profiles.

Key developments include a clinical supply agreement with BeiGene for combination therapy with tislelizumab, new patents in China, Japan, and Israel for HBV and HIV treatments, and Clinical Trial authorization from Health Canada. The company presented positive results at ASCO and SITC annual meetings.

Financial results show R&D expenses of $2.5M for Q4 2024 (up from $2.0M in Q4 2023) and $7.2M for FY2024 (down from $7.6M in FY2023). Loss per share improved to $1.61 in 2024 from $1.83 in 2023. Cash position stands at $5.8M as of December 31, 2024, with additional $2.0M raised in January 2025 and a new $20M equity line established with Yorkville in February 2025. The current cash runway extends into Q2 2025.